An Introduction to Breast Cancer
New perspectives in cancer therapy have led to rapid progress in breast cancer research. Some of the most exciting recent developments include ongoing studies aiming to enhance current breast cancer screening options, as well as approval of several poly-ADP ribose polymerase (PARP) inhibitors. Other areas of active research include histone deacetylase (HDAC) inhibitors and chimeric antigen receptor (CAR) T-cell therapies.
Browse our selection of video highlights and short articles from the conference hub, which provide insights into the latest updates from major conferences, and a collection of peer-reviewed articles from the journal portfolio. These are complemented by a range of educational activities from our expert faculty, with patient outcomes at the forefront.
Breast Cancer Content
Managing brain metastases in advanced HER2-positive breast cancer
Get up to date on the data for emerging treatment options for patients with HER2-positive breast cancer and brain metastases and how they may influence clinical practice by watching these short interviews with breast cancer experts.
- Recognize the unmet needs of patients with advanced HER2-positive breast cancer and brain metastases
- Review the clinical data for emerging treatment options for patients with advanced HER2-positive breast cancer and brain metastases
- Determine how novel HER2-targeted therapies may change the future management of patients with HER2-positive breast cancer and brain metastases
FOREWORD – ONCOLOGY & HEMATOLOGY (US) – VOLUME 16 ISSUE 1 – SPRING 2020
Welcome to the spring edition of Oncology and Hematology Review (US). During the difficult days of this COVID-19 pandemic, which has impacted cancer care worldwide, we hope our journal provides reason for optimism. We begin with one of our popular expert interviews, in which Paul G Richardson discusses the recently published O-12-M1 phase I/II study investigating […]
Why CDK 4/6 Inhibitors are Practice Changing in Advanced Breast Cancer
Oncology & Hematology Review (US). 2020;16(1):23-9 DOI: https://doi.org/10.17925/OHR.2020.16.1.23
Since the approval of palbociclib in 2015,1 cyclin dependent kinase (CDK) 4/6 inhibitors have been a heavily-researched and discussed class of medication for the management of metastatic, hormone receptor positive (HR+), human epidermal growth factor receptor 2-unamplified (HER2-) breast cancer. Because their approval and rise to prominence was based on benefit seen in progression-free survival […]
Emerging HER-targeted antibody-drug conjugates for advanced breast cancer: What are we discovering?
Watch Dr King, an internationally renowned oncology expert, discuss the latest data on human epidermal growth factor receptor-targeted antibody-drug conjugates for the treatment of breast cancer.
- Describe how the structure and mechanism of action of antibody-drug conjugates may address current unmet treatment needs in patients with advanced breast cancer
- Evaluate clinical data for emerging anti-HER2 antibody-drug conjugates used to treat patients with HER2-positive advanced breast cancer
- Discuss how clinical practice may change with the emergence of novel HER-targeted antibody-drug conjugates for patients with advanced breast cancer
From publication to practice: How trial data translate to clinical use of CDK4/6 Inhibitors in patients with HR+/HER2- advanced breast cancer
Watch leading international experts in breast cancer translate outcomes from key clinical trials investigating CDK4/6 inhibitors in HR+/HER2- advanced breast cancer into daily practice
- Identify patients with HR+/HER2- advanced breast cancer suitable for treatment with a CDK4/6 inhibitor
- Understand the key differences between the CDK4/6 inhibitors and how these might influence drug choice for individual patients
- Apply knowledge of the CDK4/6 inhibitor’s dosing, safety profile and monitoring requirements to optimize patient management
Priyanka Sharma, ASCO20: New Combination Therapy in the Treatment of Triple-Negative Breast Cancer
Priyanka Sharma, University of Kansas, joins us to discuss the data from the SWOG S1416 study (Clinicaltrials.gov identifier: NCT02595905) presented at the ASCO20 Virtual Scientific Programe on the combined use of PARP inhibitors and chemotherapy in the treatment of triple-negative breast cancer. Questions 1. What are the major unmet needs in the treatment of triple-negative […]
Anna van der Voort, ASCO20: Three-year Follow-up of the TRAIN-2 Phase III Trial
We were delighted to speak to Dr Anna van der Voort, The Netherlands Cancer Institute, to discuss her presentation at the ASCO20 Virtual Scientific Program on the long-term follow-up data of the randomised, multicentre, open-label phase III TRAIN-2 trial (ClinicalTrials.gov Identifier: NCT01996267). Questions 1. What are the major unmet needs in current neoadjuvant chemotherapy regimes […]
Javier Cortes, ASCO20: Key findings of the KEYNOTE-355 study
touchONCOLOGY were delighted to speak to Javier Cortes to discuss the key findings of the KEYNOTE-355 study, a randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer. Questions 1. What are the challenges in the treatment of triple-negative breast cancer? (0:06) 2. […]
Steve Shak, ASCO 2020: The Oncotype DX Breast Recurrence Score® Test
It was a pleasure to speak to Steve Shak from Exact Sciences anto discuss the real-world evidence from a prospective clinical survey of the Oncotype DX Breast Recurrence Score® test, accepted at the ASCO Annual Meeting. Oncotype DX is the only test that has been shown to predict the likelihood of chemotherapy benefit as well […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!